RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY

PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adolescent patients with any choroidal neovascularization etiology enrolled in the 12-month MINERVA study. METHODS: In the open-label, non-randomized study arm, ranibizumab 0.5 mg was administered to five adolescents (aged 13–17 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Hykin, Philip G., Staurenghi, Giovanni, Wiedemann, Peter, Wolf, Sebastian, Liew, Shiao Hui Melissa, Desset-Brethes, Sabine, Staines, Harry, Li, Jun, Lai, Timothy Y. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retinal Cases & Brief Reports 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219082/
https://www.ncbi.nlm.nih.gov/pubmed/30395119
http://dx.doi.org/10.1097/ICB.0000000000000825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219082/
https://www.ncbi.nlm.nih.gov/pubmed/30395119
http://dx.doi.org/10.1097/ICB.0000000000000825

Ejemplares similares